Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


eISSN: 1643-3750

Get your full text copy in PDF

Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids

Roja Rahimi, Shekoufeh Nikfar, Mohammad Abdollahi

Med Sci Monit 2007; 13(7): PI13-18

ID: 487402

TNF-alpha has an important role in the pathogenesis of ulcerative colitis (UC). It therefore seems that infliximab, the antibody against TNF-alpha, is beneficial in the treatment of UC. The aim was to determine whether infliximab induces clinical response and remission in patients with UC using the meta-analysis technique.
The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab on UC. Data from 1966 to 2006 were collected. The keywords used to search were “ulcerative colitis” with “infliximab”, “anti tumor necrosis factor”, or “anti tumor necrosis factors”. The reference lists from the retrieved articles were also reviewed for additional applicable studies.
The summary odds ratio (OR) for clinical remission in four studies was 3.24 with a 95%CI of 1.6–6.57 and a significant OR. The summary OR for clinical response in three studies was 3.93 with a 95%CI of 2.84–5.45 and a significant OR.
Infliximab is effective in inducing response and remission in patients with ulcerative colitis when administered in combination with corticosteroids.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree